

PEI Pharmacare Bulletin

Issue (2022 - 4)

April 11, 2022

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY
(EFFECTIVE DATE: (APRIL 11, 2022))

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN/PDIN	MFR
Paliperidone palmitate	Invega Trinza®	175mg/0.875ml	Prefilled syringe	02455943	PFI
		263mg/1.315ml	Prefilled syringe	02455986	
		350mg/1.75ml	Prefilled syringe	02455994	
		525mg/2.625ml	Prefilled syringe	02456001	
Criteria	For the maintenance treatment of schizophrenia and related psychotic disorders (not dementia related) in patients who have been stabilized on therapy with injectable paliperidone for at least four months.				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Seniors Drug Program, Catastrophic Drug Program				

REMOVAL OF SPECIAL AUTHORIZATION CRITERIA

Effective immediately, currently listed Sublocade® (buprenorphine) 100mg/0.5 ml syringe and 300mg/1.5 ml syringe will no longer require special authorization, and will be open benefits in currently listed programs (Financial Assistance Drug Program, Family Health Benefit Drug Program, Nursing Home Drug Program, Opioid Replacement Therapy Program, Seniors Drug Program, and Catastrophic Drug Program)

NOTICE

Effective April 28, 2022, coverage may be available for Replagal® for the treatment of Fabry Disease through the High Cost Drug Plan and Catastrophic Drug Plan, for eligible patients who meet the criteria set out in the Canadian Fabry Disease Treatment Guidelines. The treatment guidelines are supported by the Canadian Fabry Disease Initiative (CFDI), and may be amended by the CFDI from time to time.

Please contact the PEI Pharmacare Program office at [1-877-577-3737](tel:1-877-577-3737) for more information regarding coverage availability and the Special Authorization application process for this product.